Literature DB >> 11543678

Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking.

H S Kim1, D Barak, T K Harden, J L Boyer, K A Jacobson.   

Abstract

The activation of P2Y1 receptors in platelets contributes to platelet aggregation, and selective antagonists are sought as potential antithrombotic agents. We reported (Kim et al. J. Med. Chem. 2000, 43, 746-755) that acyclic analogues of adenine nucleotides, containing two phosphate groups on a symmetrically branched aliphatic chain, attached at the 9-position of adenine, are moderately potent P2Y1 receptor antagonists. In this study we have varied the chain structure, to include asymmetric substitution, olefinic, and cyclopropyl groups. These antagonists inhibited the stimulation of phospholipase C in turkey erythrocyte membranes induced by 30 nM 2-MeS-ADP in the micromolar range. In the series of symmetrically branched aliphatic groups substituted with two phosphate groups, the optimal antagonist potency occurred with the 2-methylpropyl group. A 2-chloro-N(6)-methyladenine derivative, 2-[2-(2-chloro-6-methylaminopurin-9-yl)methyl]propane-1,3-bisoxy(diammoniumphosphate) (7), was a full antagonist at the P2Y1 receptor with an IC(50) value of 0.48 microM. Esterification of one of the phosphate groups or substitution with O-acetyl greatly reduced the antagonist potency at the P2Y1 receptor. Removal of a methylene group of 7 or inclusion of an olefinic or cyclopropyl group also reduced potency. A pair of enantiomeric glycerol derivatives demonstrated a 5-fold stereoselectivity for the S-isomer. Stereoisomerically defined analogues of 7 containing a cyclopropyl group in place of the branched carbon were less potent than 7 as antagonists, with IC(50) values of 2-3 microM. No agonist activity was observed for these analogues. A new rhodopsin-based molecular model of the P2Y1 receptor indicated that the optimal docked orientation of the two monophosphate moieties relative to the adenine N(6) (compared to a rigid, bicyclic analogue) was consistent with the dependence of antagonist potency on chain length. The 3'-phosphate was predicted to occupy a restricted space, deeper in the binding cleft than the 5'-phosphate location. In summary, modification of the flexible spacer chain linking bisphosphate groups to the adenine moiety provided many moderately potent antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11543678      PMCID: PMC9370770          DOI: 10.1021/jm010082h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  33 in total

1.  Towards a revised nomenclature for P1 and P2 receptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; G R Dubyak; T K Harden; K A Jacobson; U Schwabe; M Williams
Journal:  Trends Pharmacol Sci       Date:  1997-03       Impact factor: 14.819

2.  Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.

Authors:  J E Fabre; M Nguyen; A Latour; J A Keifer; L P Audoly; T M Coffman; B H Koller
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

3.  Modelling the P2Y purinoceptor using rhodopsin as template.

Authors:  A M Van Rhee; B Fischer; P J Van Galen; K A Jacobson
Journal:  Drug Des Discov       Date:  1995-11

4.  Kinetics of activation of phospholipase C by P2Y purinergic receptor agonists and guanine nucleotides.

Authors:  J L Boyer; C P Downes; T K Harden
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

5.  An all atom force field for simulations of proteins and nucleic acids.

Authors:  Scott J Weiner; Peter A Kollman; Dzung T Nguyen; David A Case
Journal:  J Comput Chem       Date:  1986-04       Impact factor: 3.376

6.  (2R,1'S,2'R,3'S)-2-(2'-Carboxy-3'-phenylcyclopropyl)glycine (PCCG-13), the first potent and selective competitive antagonist of phospholipase D-coupled metabotropic glutamate receptors: asymmetric synthesis and preliminary biological properties.

Authors:  R Pellicciari; M Marinozzi; G Costantino; B Natalini; F Moroni; D Pellegrini-Giampietro
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

7.  Acyclic analogues of deoxyadenosine 3',5'-bisphosphates as P2Y(1) receptor antagonists.

Authors:  Y C Kim; C Gallo-Rodriguez; S Y Jang; E Nandanan; M Adams; T K Harden; J L Boyer; K A Jacobson
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

8.  Potent inhibitors of human inosine monophosphate dehydrogenase type II. Fluorine-substituted analogues of thiazole-4-carboxamide adenine dinucleotide.

Authors:  A Zatorski; B M Goldstein; T D Colby; J P Jones; K W Pankiewicz
Journal:  J Med Chem       Date:  1995-03-31       Impact factor: 7.446

9.  Expression of a cloned P2Y purinergic receptor that couples to phospholipase C.

Authors:  T M Filtz; Q Li; J L Boyer; R A Nicholas; T K Harden
Journal:  Mol Pharmacol       Date:  1994-07       Impact factor: 4.436

10.  Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate.

Authors:  J L Boyer; A Mohanram; E Camaioni; K A Jacobson; T K Harden
Journal:  Br J Pharmacol       Date:  1998-05       Impact factor: 8.739

View more
  27 in total

1.  Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.

Authors:  Gary L Waldo; James Corbitt; José L Boyer; Gnana Ravi; Hak Sung Kim; Xiao-Duo Ji; James Lacy; Kenneth A Jacobson; T Kendall Harden
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

Review 2.  Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Michihiro Ohno; Bhalchandra V Joshi; Pedro Besada; Bin Xu; Susanna Tchilibon
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

3.  [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.

Authors:  Dayle Houston; Michihiro Ohno; Robert A Nicholas; Kenneth A Jacobson; T Kendall Harden
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

4.  Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases.

Authors:  Petra Břehová; Markéta Šmídková; Jan Skácel; Martin Dračínský; Helena Mertlíková-Kaiserová; Monica P Soto Velasquez; Val J Watts; Zlatko Janeba
Journal:  ChemMedChem       Date:  2016-10-24       Impact factor: 3.466

5.  Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling.

Authors:  Andrei A Ivanov; Stefano Costanzi; Kenneth A Jacobson
Journal:  J Comput Aided Mol Des       Date:  2006-10-03       Impact factor: 3.686

6.  Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.

Authors:  Keith Clinch; Gary B Evans; Richard F G Fröhlich; Richard H Furneaux; Peter M Kelly; Laurent Legentil; Andrew S Murkin; Lei Li; Vern L Schramm; Peter C Tyler; Anthony D Woolhouse
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

7.  Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling.

Authors:  Stefano Costanzi; Liaman Mamedova; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2004-10-21       Impact factor: 7.446

8.  P2Y(1) receptors mediate inhibitory neuromuscular transmission in the rat colon.

Authors:  Laura Grasa; Víctor Gil; Diana Gallego; Maria Teresa Martín; Marcel Jiménez
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

Review 9.  The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors.

Authors:  Slawomir Filipek; David C Teller; Krzysztof Palczewski; Ronald Stenkamp
Journal:  Annu Rev Biophys Biomol Struct       Date:  2003-02-05

10.  Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow.

Authors:  Mario Mazzucato; Maria Rita Cozzi; Monica Battiston; Martine Jandrot-Perrus; Maurizio Mongiat; Patrizia Marchese; Thomas J Kunicki; Zaverio M Ruggeri; Luigi De Marco
Journal:  Blood       Date:  2009-07-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.